Abstract
Colorectal cancer (CRC) is the fourth most common malignant disease. Of newly diagnosed patients, 40% have metastatic disease at diagnosis, and approximately 25% of patients with localized disease at diagnosis will ultimately develop metastatic disease. The benefits of systemic chemotherapy in the treatment of metastatic colorectal cancer over best supportive care have been established. The epidermal growth factor receptor (EGFR) is overexpressed in the 80% of colorectal cancer and correlate with a poor prognosis. Cetuximab (C225, Erbitux TM) is chimeric human-mouse G1 immunoglobulin that binds to the EGFR with a 10-fold higher affinity than the natural ligands TGF?? and EGF. Cetuximab is currently licensed worldwide for the treatment of irinotecan-refractory metastatic CRC disease. It is well tolerated and the major adverse event is skin rash which also correlates with clinical response to treatment. An extensive phase II and III program of evaluation of cetuximab activity and efficacy in different settings of metastatic CRC has been undertaken. This article will review the current knowledge on the role of cetuximab in the medical management of metastatic CRC.
Keywords: Cetuximab, metastatic colorectal cancer, chimeric anti-EGFR monoclonal antibody
Current Cancer Therapy Reviews
Title: Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment
Volume: 3 Issue: 4
Author(s): Erika Martinelli, Michele Orditura, Ferdinando De Vita, Gennaro Galizia and Fortunato Ciardiello
Affiliation:
Keywords: Cetuximab, metastatic colorectal cancer, chimeric anti-EGFR monoclonal antibody
Abstract: Colorectal cancer (CRC) is the fourth most common malignant disease. Of newly diagnosed patients, 40% have metastatic disease at diagnosis, and approximately 25% of patients with localized disease at diagnosis will ultimately develop metastatic disease. The benefits of systemic chemotherapy in the treatment of metastatic colorectal cancer over best supportive care have been established. The epidermal growth factor receptor (EGFR) is overexpressed in the 80% of colorectal cancer and correlate with a poor prognosis. Cetuximab (C225, Erbitux TM) is chimeric human-mouse G1 immunoglobulin that binds to the EGFR with a 10-fold higher affinity than the natural ligands TGF?? and EGF. Cetuximab is currently licensed worldwide for the treatment of irinotecan-refractory metastatic CRC disease. It is well tolerated and the major adverse event is skin rash which also correlates with clinical response to treatment. An extensive phase II and III program of evaluation of cetuximab activity and efficacy in different settings of metastatic CRC has been undertaken. This article will review the current knowledge on the role of cetuximab in the medical management of metastatic CRC.
Export Options
About this article
Cite this article as:
Martinelli Erika, Orditura Michele, Vita De Ferdinando, Galizia Gennaro and Ciardiello Fortunato, Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment, Current Cancer Therapy Reviews 2007; 3 (4) . https://dx.doi.org/10.2174/157339407782497068
DOI https://dx.doi.org/10.2174/157339407782497068 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gene Expression Analysis Approach to Establish Possible Links Between Parkinson's Disease, Cancer and Cardiovascular Diseases
CNS & Neurological Disorders - Drug Targets Genomics-Based Identification of Molecular Mechanisms behind the Cancer Preventive Action of Phytochemicals: Potential and Challenges
Current Pharmaceutical Biotechnology Evolutionary Significance of Iodine
Current Chemical Biology Regulation of Autophagy in Oxygen-Dependent Cellular Stress
Current Pharmaceutical Design Biomarkers for Systemic Therapy in Ovarian Cancer
Current Cancer Drug Targets Dendrimer-Curcumin Conjugate: A Water Soluble and Effective Cytotoxic Agent Against Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Melanoma and Epigenetic Treatment: Past and Future
Anti-Cancer Agents in Medicinal Chemistry BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
Current Cancer Drug Targets Transmembrane Protein 166 and its Significance
Protein & Peptide Letters Mesenchymal Stem Cells: An Emerging Tool for Cancer Targeting and Therapy
Current Stem Cell Research & Therapy Immunonutrition in Surgical Patients
Current Drug Targets Aromatase Inhibitors: A New Reality for the Adjuvant Endocrine Treatment of Early-Stage Breast Cancer in Postmenopausal Women
Mini-Reviews in Medicinal Chemistry Heterocycle-thioacetic Acid Motif: A Privileged Molecular Scaffold with Potent, Broad-Ranging Pharmacological Activities
Current Pharmaceutical Design Regulation of Leptin Receptor Expression in Human Polarized Caco-2/15 Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Biological Roles of Ursolic Acid in the Treatment of Human Diseases
Current Bioactive Compounds Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Statins and Type 2 Diabetes Mellitus: An Update After 1 Year
Current Pharmaceutical Design CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis
Current Drug Safety Focal Adhesion Kinase as a Cancer Therapy Target
Anti-Cancer Agents in Medicinal Chemistry The Role of Histone Demethylase GASC1 in Cancer and its Therapeutic Potential
Current Cancer Therapy Reviews